by The global Unit Dose Manufacturing market size is expected to be worth around US$ 70.5 billion by 2030, according to a new report by Vision Research Reports.
The global Unit Dose Manufacturing market size was valued at US$ 17.0 billion in 2020 and is anticipated to grow at a CAGR of 19.2% during forecast period 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39076
Table of Contents
Unit Dose Manufacturing Market Growth Factors
In the first half of 2020, the growth of the market was stagnant, but the market started to recover by the end of 2020. It was mainly due to the use of unit doses for the treatment of COVID-19 as it decreases the risk involved while handling and pouring doses from the same bottle.
Unit dose manufacturing has many advantages as the drug can be easily identified, and the formulation of the drug is protected until the moment of administration. If the container is intact and the drug has not been used, it can be redisposed and retrieved without changing its formulation. The most important benefit is that it can be administered in the proper dosage and ensures that the patient does not exceed the prescribed limit.
However, the COVID-19 pandemic has a significant effect on the pharmaceutical market. The first half of the COVID-19 pandemic had slowed growth but by the end of 2020, the market started to recover. The unit dose manufacturing is lucratively used in the current scenario as it reduces the risk of handling and contamination.
Unit Dose Manufacturing Market Report Coverage
| Report Scope | Details |
| Market Size | US$ 70.5 billion by 2030 |
| Growth Rate | CAGR of 19.2% From 2021 to 2030 |
| Largest Market | North America |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Sourcing, Product, End-use |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Catalent Inc.; Patheon (Thermo fisher); Unither; Tapemark; Mikart; Renaissance Lakewood, LLC; Medical packaging, Inc.; CordenPharma; American Health Packaging |
By Sourcing Analysis
The outsourcing segment dominated the market with a revenue share of over 56.0% in 2020. The market is estimated to become 3.55 times of itself by 2030. This segment is also expected to grow at the fastest rate over the forecasted period.
Pharmaceutical companies that manufacture unit dosages are included in the in-house segment. The in-house segment is projected to exhibit gradual growth over the forecasted period due to increasing outsourcing activity.
By Product Analysis
The solid unit dose segment dominated the market and accounted for over 46.0% share of the global revenue in 2020. This growth is due to the formulations having a better shelf life. Besides, they are cost-effective, efficient, and simple to use. The solid dose is well understood, and it is accepted globally.
The solid unit dose is expected to witness rapid expansion in the coming years. This is due to fixed-dose combinations, controlled-release dosage forms, and reformulations of existing drugs, which are some of the factors that are driving the contract manufacturing of solid dosage formulations.
By End-use Analysis
The independent pharmacies segment accounted for the largest revenue share of over 31.0% in 2020. It is estimated to become 4.01 times of itself by 2020. The segment is also anticipated to register the fastest growth rate over the forecast period.
The hospitals segment accounted for the second-largest revenue share in 2020. Unit dose packaging is extremely beneficial in hospitals. In hospitals and long-term care institutions, small improvements make it safer and more efficient for patients and health personnel.
By Regional Analysis
The North American market held the largest revenue share of over 35.0% in 2020. A patient-centric drug development approach is adopted by most drug product manufacturers, big pharma companies, generics, and nutraceutical segments.
The growth of unit dose manufacturing in North America is due to high healthcare expenditure, well-established healthcare infrastructure, the presence of dominant market players, and the flourishing pharmaceutical industry in the region.
Read also @ Immunohistochemistry Market to Expand at a CAGR of 7.2% from 2021 to 2030
Major Key Players Covered in The Unit Dose Manufacturing Market Report include
- Catalent Inc.
- Patheon (Thermo fisher)
- Unither
- Tapemark
- Mikart
- Renaissance Lakewood, LLC
- Medical packaging, Inc.
- CordenPharma
- American Health Packaging
Unit Dose Manufacturing Market Segmentation
- By Sourcing
- In-house
- Outsourcing
- By Product
- Liquid Unit Dose
- Solid Unit Dose
- Others
- By End-use
- Independent Pharmacies
- Long Term Care Facility
- Hospitals
- Others
- Regional
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Asia Pacific
- India
- Japan
- China
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Unit Dose Manufacturing Market, By Sourcing
7.1. Unit Dose Manufacturing Market, by Sourcing, 2021-2030
7.1.1. In-house
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Outsourcing
7.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Unit Dose Manufacturing Market, By Product
8.1. Unit Dose Manufacturing Market, by Product, 2021-2030
8.1.1. Liquid Unit Dose
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Solid Unit Dose
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Unit Dose Manufacturing Market, By End User
9.1. Unit Dose Manufacturing Market, by End User, 2021-2030
9.1.1. Independent Pharmacies
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Long Term Care Facility
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Hospitals
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Unit Dose Manufacturing Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.1.2. Market Revenue and Forecast, by Product (2017-2030)
10.1.3. Market Revenue and Forecast, by End User (2017-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Product (2017-2030)
10.1.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.1.5.2. Market Revenue and Forecast, by Product (2017-2030)
10.1.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.2.2. Market Revenue and Forecast, by Product (2017-2030)
10.2.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Product (2017-2030)
10.2.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Product (2017-2030)
10.2.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Product (2017-2030)
10.2.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.2.7.2. Market Revenue and Forecast, by Product (2017-2030)
10.2.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.3.2. Market Revenue and Forecast, by Product (2017-2030)
10.3.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Product (2017-2030)
10.3.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Product (2017-2030)
10.3.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Product (2017-2030)
10.3.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.3.7.2. Market Revenue and Forecast, by Product (2017-2030)
10.3.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.4.2. Market Revenue and Forecast, by Product (2017-2030)
10.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Product (2017-2030)
10.4.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Product (2017-2030)
10.4.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Product (2017-2030)
10.4.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.4.7.2. Market Revenue and Forecast, by Product (2017-2030)
10.4.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.5.2. Market Revenue and Forecast, by Product (2017-2030)
10.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Product (2017-2030)
10.5.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Sourcing (2017-2030)
10.5.5.2. Market Revenue and Forecast, by Product (2017-2030)
10.5.5.3. Market Revenue and Forecast, by End User (2017-2030)
Chapter 11. Company Profiles
11.1. Catalent Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Patheon (Thermo fisher)
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Unither
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Tapemark
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Mikart
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Renaissance Lakewood, LLC
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Medical packaging, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. CordenPharma
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. American Health Packaging
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39076
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
